Martin Sabel
MD
Director, Breast Center
👥Biography 个人简介
Martin Sabel at Dusseldorf contributed to establishing immunotherapy in early triple-negative breast cancer. The KEYNOTE-522 trial — which showed that adding pembrolizumab to neoadjuvant chemotherapy and continuing it as adjuvant therapy improved pathologic complete response and event-free survival in early TNBC — established a new standard of care that German centers including Dusseldorf helped implement and contribute to.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-03-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Martin Sabel 的研究动态
Follow Martin Sabel's research updates
留下邮箱，当我们发布与 Martin Sabel（University Hospital Dusseldorf）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment